Sax Wealth Advisors LLC Purchases 617 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sax Wealth Advisors LLC grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 76.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,426 shares of the company’s stock after acquiring an additional 617 shares during the quarter. Sax Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $590,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in IDXX. Chicago Partners Investment Group LLC grew its holdings in IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after acquiring an additional 96 shares during the last quarter. National Pension Service boosted its stake in IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company’s stock worth $93,957,000 after acquiring an additional 12,647 shares in the last quarter. Insight Wealth Strategies LLC grew its stake in IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after acquiring an additional 7,041 shares during the period. Larson Financial Group LLC lifted its holdings in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after purchasing an additional 2,241 shares in the last quarter. Finally, Quest Partners LLC lifted its position in shares of IDEXX Laboratories by 4,059.4% during the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after purchasing an additional 2,801 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays decreased their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $523.86.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Down 2.2 %

Shares of IDEXX Laboratories stock opened at $419.26 on Friday. The company’s fifty day simple moving average is $423.60 and its two-hundred day simple moving average is $458.13. The company has a market cap of $34.33 billion, a P/E ratio of 40.43, a PEG ratio of 3.52 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm’s revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.53 earnings per share. Research analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.